SSY GROUP(02005.HK): Trustee Purchases 2 Million Shares Under Restricted Share Award Scheme at Average Price of HK$2.1585
NewTimeSpace News: SSY Group Limited (02005.HK) announced on 23 June that the trustee acquired 2 million shares on the open market pursuant to the Restricted Share Award Scheme at an average price of HK$2.1585 per share, with total consideration of approximately HK$4.317 million. Following the purchase, the trustee holds 9.68 million shares, accounting for 0.328% of the total issued share capital.
NewTimeSpace News: On 23 June 2026, SSY Group Limited (02005.HK) issued a voluntary announcement stating that on the date of this announcement, funded by the Group’s internal resources, the scheme trustee purchased an aggregate of 2,000,000 shares of the Company on the open market in accordance with the terms of the Restricted Share Award Scheme. The purchased shares represent approximately 0.068% of the total number of issued shares as at present. The average consideration per share was around HK$2.1585, and the total consideration amounted to approximately HK$4,317,000 (excluding expenses). Immediately after the purchase, the balance of shares held by the trustee stood at 9,680,000 shares, equivalent to roughly 0.328% of the current total issued shares.
The Company adopted the Restricted Share Award Scheme on 27 December 2018. The Board of Directors will review the scheme from time to time and exercise full discretion to determine the number of shares to be granted to selected participants.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags:
- SSY GROUP(02005.HK): NMPA Grants Manufacturing Approval for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution
- SSY Group(02005.HK): Trustee Purchases 380,000 Shares on Open Market Under Restricted Share Award Scheme at Average Price of HK$2.2124
- SSY Group Signs Letter of Intent with Longhai Pharma for Four Biosimilars Including Ustekinumab and Dupilumab
- SSY Group (02005.HK) Secures Production Approval for Four Drugs; Second Domestic Firm to Launch Emedastine Difumarate Eye Drops
- SSY Group (02005.HK): Obtains Production Registration Approvals for Three Products; Fat-Soluble Vitamin Injection Approved as First Domestic Enterprise